Predictive and Prognostic Roles of Ribonucleotide Reductase M1 in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4261-4265

  Zhang, Xiong ^a   Jin, Fen Shu ^a   Zhang, Li Guo ^a   Chen, Rui Xue ^a   Zhao, Jin Hui ^a   Wang, Yan Nan ^a   Wang, En Fu ^a   Jiang, Zhen Dong ^a  

^a Hubei Wuchang Hospital ^*  (China)

Author keywords

Gemcitabine; Meta analysis; Pancreatic cancer; Ribonucleotide reductase M1

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; HUMAN; META ANALYSIS; METABOLISM; MORTALITY; PANCREAS TUMOR; PROGNOSIS; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84885454239     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4261     Document Type: Article

References (35)

1. Akita H, Zheng Z, Takeda Y, et al (2009). Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene, 28, 2903-9.
2. Bepler G, Kusmartseva I, Sharma S, et al (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol, 24, 4731-7.
3. Biggerstaff BJ, Jackson D (2008). The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis. Stat Med, 27, 6093-110.
4. Choi M, Kim R, Saif MW (2012). What options are available for refractory pancreatic cancer? JOP, 13, 163-5.
5. Fujita H, Ohuchida K, Mizumoto K, et al (2010). Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia, 12, 807-17.
6. Giovannetti E, Mey V, Nannizzi S, et al (2006). Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther, 5, 1387-95.
7. Hsu CC, Herman JM, Corsini MM, et al (2010). Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol, 17, 981-90.
8. Jackson D, White IR, Riley RD (2012). Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med, 31, 3805-20.
9. Jordheim LP, Seve P, Tredan O, et al (2011). The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol, 12, 693-702.
10. Kanai M, Yoshimura K, Asada M, et al (2011). A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol, 68, 157-64.
11. Kim R, Tan A, Lai KK, et al (2011a). Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer, 117, 3126-34.
12. Kim ST, Lim do H, Jang KT, et al (2011b). Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther, 10, 1993-9.
13. Kovacevic Z, Chikhani S, Lovejoy DB, et al (2011). Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol, 80, 598-609.
14. Kwon WS, Rha SY, Choi YH, et al (2006). Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics, 16, 429-38.
15. Lai R, Bartlett NL, Mackey JR, et al (2008). High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Leuk Lymphoma, 49, 1202-5.
16. Lau MK, Davila JA, Shaib YH (2010). Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas, 39, 458-62.
17. Li D, Xie K, Wolff R, et al (2004). Pancreatic cancer. Lancet, 363, 1049-57.
18. Marechal R, Bachet JB, Mackey JR, et al (2012). Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology, 143, 664-74 e1-6.
19. Mini E, Nobili S, Caciagli B, et al (2006). Cellular pharmacology of gemcitabine. Ann Oncol, 17, v7-12.
20. Nakagawa N, Murakami Y, Uemura K, et al (2013). Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery, 153, 565-75.
21. Nakahira S, Nakamori S, Tsujie M, et al (2007). Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer, 120, 1355-63.
22. Neoptolemos JP, Stocken DD, Bassi C, et al (2010). Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA, 304, 1073-81.
23. Oettle H, Post S, Neuhaus P, et al (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA, 297, 267-77.
24. Ohtaka K, Kohya N, Sato K, et al (2008). Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep, 20, 279-86.
25. Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80.
26. Siegel R, Naishadham D and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
27. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5.
28. Traverso LW (2006). Pancreatic cancer: surgery alone is not sufficient. Surg Endosc, 20, S446-9.
29. Ueno H, Kiyosawa K and Kaniwa N (2007). Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer, 97, 145-51.
30. Valsecchi ME, Holdbrook T, Leiby BE, et al (2012). Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer, 12, 104.
31. Van Laethem JL, Hammel P, Mornex F, et al (2010). Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol, 28, 4450-6.
32. Wang Z, Li Y, Kong D, et al (2009). Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res, 69, 2400-7.
33. Wonganan P, Chung WG, Zhu S, et al (2012). Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol Ther, 13, 908-14.
34. Xie H, Jiang W, Jiang J, et al (2013). Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer, 119, 173-81.
35. Ying JE, Zhu LM, Liu BX (2012). Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol, 18, 736-45.